For the first time, a comprehensive guideline for #ADPKD care is available. Developed by @goKDIGO global experts, including #TuftsMedicine @TuftsMCKidney's Dr. Ronald Perrone + Dr. @Gordon7Craig, it provides the latest recommendations. Learn more: https://bit.ly/42PuonJ
Great infographic on the risk factors for ADPKD progression
Clinical features factors graded as per the strength of association - from the latest KDIGO-ADPKD-2025 guidelines👌@goKDIGO
Publication dates are typically determined by the publisher after guideline submission and can change based on journal publication timelines.
Graded recommendations are based on a systematic evidence review and graded for the strength of the recommendation and certainty of evidence following the GRADE methodology. Practice points are consensus statements about a specific aspect of care, and they supplement recommendations for which a larger quantity of evidence was identified.
Level 1 recommendations are strong recommendations for clinical practice, indicating that most people would want the recommended course of action, and only a small proportion would not. These recommendations begin with “We recommend.” Level 2 recommendations indicate that the majority of people would want the recommended course of action, but many would not, meaning that
Graded recommendations are based on a systematic evidence review and graded for the strength of the recommendation and certainty of evidence following the GRADE methodology. Practice points are consensus statements about a specific aspect of care, and they supplement recommendations for which a larger quantity of evidence was identified.
KDIGO Guidelines should be cited using the citation format provided in each guideline document and on the KDIGO Citations page.
KDIGO makes all guidelines available for public review before submitting the final manuscript for publication. Feedback can be provided during Public Review periods. All comments must be submitted via the KDIGO Public Review Feedback Survey, which is circulated as part of the Public Review announcement. Subscribe to KDIGO communications to receive updates on KDIGO Public
Yes, KDIGO Guidelines are updated to incorporate new evidence and advancements in the field. KDIGO is working to expedite the rate at which guidelines are updated.
Updates to KDIGO Guidelines are triggered by: Substantial New Evidence: Availability of new research that may change existing recommendations Advancements in Treatment: Introduction of management strategies that improve patient outcomes. Feedback from the Medical Community: Insights from practitioners and stakeholders indicating areas needing revision Periodic Reassessment: Need for an update to a guideline that is
KDIGO has published numerous guidelines covering various aspects of kidney disease, including: Acute Kidney Injury (AKI) Anemia in Chronic Kidney Disease (CKD) Autosomal Dominant Polycystic Kidney Disease (ADPKD) Blood Pressure in CKD CKD Evaluation and Management CKD-Mineral and Bone Disorder (CKD-MBD) Diabetes in CKD Glomerular Diseases Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis IgA Nephropathy (IgAN) /
Published KDIGO Guidelines are freely accessible on the KDIGO website. You can view and download them directly from the “Guidelines” section, which lists all available guidelines by topic. Electronic publications of KDIGO Guidelines are also available for free in the peer-reviewed journal in which the guideline was published. KDIGO does not print its guidelines.
Developing a KDIGO de novo guideline takes approximately 2-3 years, depending on the complexity of the topic and breadth of the Scope of Work, the identification and evaluation of the literature, feedback from the Public Review, and the publisher’s timeline. Guideline updates are typically faster than de novo reviews, with publication within 18 months.
Work Group members are selected by KDIGO and Guideline Co-Chairs for their lived experience, expertise in the relevant field, including clinical practice or research, or experience in guideline development methodology. KDIGO seeks to ensure: Multidisciplinary Representation: Including various specialties to provide comprehensive insights Geographic Diversity: Incorporating perspectives from different regions to enhance global applicability Patient
Topics are selected by the KDIGO Executive Committee based on criteria like disease burden, clinical need, evidence availability, potential impact, and alignment with the KDIGO mission. Stakeholder input and insights from KDIGO Controversies Conferences may also inform topic selection. KDIGO prioritizes topics based on several criteria: Burden of Illness: Assessing the prevalence and severity of
A de novo guideline is a brand-new guideline developed on a topic for which there is no existing KDIGO guideline. A guideline update revises an existing KDIGO guideline based on new evidence and advancements in the field.
KDIGO develops its clinical practice guidelines through a rigorous, evidence-based process in line with international best practices for guideline development. The steps include: Topic Selection: Prioritizing topics based on disease burden, prevalence, and potential impact on patient outcomes Work Group Formation: Assembling a diverse group of experts with clinical, research, and methodological expertise, as well
